文献速递乳腺癌

SB3曲妥珠单抗生物类似药对比原研药:HER2阳性早期乳腺癌新辅助-辅助治疗最终安全性、免疫原性与生存结果

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
PubMed 文献 · Eur J Cancer · 2018-02-12

这项III期研究将875例HER2阳性早期或局部晚期乳腺癌患者按1:1随机分组,在新辅助化疗同时分别接受SB3或原研曲妥珠单抗8周期,术后继续辅助治疗10周期。最终分析显示两组治疗中出现的不良事件发生率相近(SB3 97.5% vs 原研 96.1%),抗药抗体发生率均低(各3例),12个月无事件生存率分别为93.7%和93.4%,风险比为0.94(95%CI 0.59-1.51),进一步支持SB3与原研药的生物相似性。

要点

  • SB3与原研曲妥珠单抗在新辅助-辅助治疗中的安全性、免疫原性及生存结果相当。
  • 总体治疗中出现的不良事件发生率SB3为97.5%、原研为96.1%。
  • 12个月无事件生存率SB3为93.7%、原研为93.4%,HR=0.94(95%CI 0.59-1.51)。

核心结论

  • 最终安全性、免疫原性与生存结果进一步支持SB3与原研曲妥珠单抗之间已建立的生物相似性。

研究设计与样本

  • III期随机研究,875例HER2阳性早期或局部晚期乳腺癌患者按1:1随机接受新辅助SB3或原研曲妥珠单抗8周期联合化疗,术后辅助10周期。
  • 764例完成研究(SB3组380例,原研组384例);中位随访时间SB3组437天、原研组438天。

主要发现

  • 总体研究期间治疗中出现的不良事件发生率两组相近:SB3为97.5%,原研为96.1%。
  • 截至研究结束,抗药抗体总体发生率两组均低(各3例)。
  • 无事件生存两组相当,风险比(SB3/原研)为0.94(95%CI 0.59-1.51);12个月无事件生存率SB3为93.7%、原研为93.4%。

临床怎么用

  • 本研究结果支持在HER2阳性早期乳腺癌的新辅助-辅助治疗中,SB3可作为原研曲妥珠单抗的生物类似药选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide). Patients then underwent surgery, followed by 10 cycles of adjuvant SB3 or TRZ as randomised. End-points included safety, immunogenicity, event-free survival (EFS) and overall survival through the adjuvant period. RESULTS: Of 875 patients randomised, 764 (SB3, n = 380; TRZ, n = 384) completed the study. The median follow-up duration was 437 days in the SB3 group and 438 days in the TRZ group. The incidence of treatment-emergent adverse events was comparable between groups (SB3, 97.5%; TRZ, 96.1%) during the overall study period. Up to the end of study, the overall incidence of antidrug antibody was low in both treatment groups (3 patients each). EFS was comparable between groups with a hazard ratio (SB3/TRZ) of 0.94 (95% confidence interval, 0.59-1.51) and EFS rates at 12 months of 93.7% for SB3 and 93.4% for TRZ. CONCLUSIONS: Final safety, immunogenicity and survival results of this study further support the biosimilarity established between SB3 and TRZ. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02149524); EudraCT (2013-004172-35).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pivot X, Bondarenko I, Nowecki Z, et al. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. Eur J Cancer. 2018. PMID: 29448072. doi:10.1016/j.ejca.2018.01.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。